Leading international society embarks on
multi-year initiative to increase clinician awareness of factor
XI/XIa inhibition
BANGKOK,
June 21,
2024 /PRNewswire/ -- The International Society on
Thrombosis and Haemostasis (ISTH), the leading worldwide
not-for-profit organization dedicated to advancing the
understanding, prevention, diagnosis, and treatment of conditions
related to thrombosis and hemostasis, announces the official launch
of new education titled "ISTH Emerging Therapies in
Thrombosis—Factor XI/XIa Inhibitors". The organization is embarking
on a comprehensive, globally relevant educational initiative to
increase clinician awareness of factor XI (FXI) inhibition and how
it might lead to the development of safer anticoagulation
therapy.
In early 2023, the ISTH organized the
multi-disciplinary, international Factor XI/XIa Educational
Steering Committee, a group of world-renowned experts led by
Jeff Weitz, MD, to survey a sample
of the multi-disciplinary target audiences for this education.
By utilizing the results of the survey, with
input from other educational sources, the committee designed a
dynamic educational roadmap to guide the development of the factor
XI/XIa multi-year initiative.
The ISTH will develop a centralized and branded
learning center called the "Learning Hub" that will be integrated
within the ISTH Academy, an online platform providing Society
members with premier access to educational resources. It will be
launched in conjunction with an in-person learning experience
on-site at the ISTH Academy booth at the ISTH's 2024 Congress in
Bangkok, Thailand, from
June 22-26, 2024.
The in-person learning experience will focus on
the topic The Promise of Factor XI/XIa Inhibitors:
Anticoagulation Without the Risk of Bleeding. This 20-minute
lecture will be recorded and broadcast in the ISTH Academy booth
throughout the meeting and shared on the ISTH Academy after the
Congress.
"Launching the factor XI/XIa educational roadmap
in Bangkok is an exciting
opportunity to kick off this global education initiative," said
Weitz, the ISTH's recently elected Secretary General for 2024-2028
term. "Our leadership in the steering committee and feedback from
the greater thrombosis and hemostasis community has allowed us to
understand the current needs and create meaningful education in
factor XI/XIa inhibition."
The offerings inside the Learning Hub on the ISTH
Academy platform will include:
- The results of the survey and a factor XI/XIa educational
roadmap
- A glossary of terms to aid learners in understanding current
and evolving terminology related to FXI/XIa inhibition
- Educational content developed by the ISTH and links to
external resources
- A research round-up, a collation of current trials and research
for all FXI/XIa inhibitor indications under investigation
- Subscription-style updates, allowing the ISTH to provide
new research and educational activities that will be released
throughout the year
ISTH Emerging Therapies in Thrombosis—Factor
XI/XIa Inhibitors is supported by educational grants from Bayer,
Anthos, and BMS/J&J. For more information, visit this
link.
About the International Society on Thrombosis
and Haemostasis (ISTH)
Founded in 1969, the ISTH is the
leading worldwide not-for-profit organization dedicated to
advancing the understanding, prevention, diagnosis, and treatment
of conditions related to thrombosis and hemostasis. ISTH is an
international medical-scientific professional membership
organization with more than 7,500 clinicians, researchers, and
educators working together to improve the lives of patients in more
than 110 countries around the world. Among its highly regarded
activities and initiatives are education and standardization
programs, research activities, meetings and congresses,
peer-reviewed publications, expert committees, and World Thrombosis
Day on 13 October. Visit ISTH online at www.isth.org.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isth-announces-launch-of-new-global-education-initiative-in-factor-xixia-inhibition-302174715.html
SOURCE International Society on Thrombosis and Haemostasis